# HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

> **NCT07175415** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 42 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Venetoclax
- **DEVICE:** Dexamethasone
- **DRUG:** Intrathecal chemotherapy

## Key facts

- **NCT ID:** NCT07175415
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2031-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175415, "HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07175415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*